Be a part of us in returning to NYC on June fifth to collaborate with govt leaders in exploring complete strategies for auditing AI fashions relating to bias, efficiency, and moral compliance throughout numerous organizations. Discover out how one can attend right here.
Atropos Well being, a healthcare know-how firm targeted on producing customized real-world proof, introduced right now that it has raised $33 million in a Sequence B funding spherical. The spherical included strategic investments from healthcare giants McKesson, Merck, and Cencora Ventures, signaling robust business curiosity in Atropos’ mission to carry automated, high-quality proof to affected person care choices.
The Silicon Valley-based startup plans to make use of the brand new capital to increase its operations and double down on key initiatives similar to launching in life sciences, increasing channel partnerships in value-based care and oncology, and rising its proof community of knowledge companions.
“We’re on a mission to carry customized proof for care to everyone on the planet. So it’s one other step in that journey,” stated Atropos Well being CEO and co-founder, Brigham Hyde, PhD, in an interview with VentureBeat. “Particularly, we’ll be utilizing this to double down behind our strategic initiatives, which embody persevering with our launch in life sciences and constructing on the good traction we now have there, additionally doubling down behind channel companions, significantly in value-based care and specialty care oncology.”
Shaping the way forward for healthcare supply with AI-powered scientific proof technology
Atropos’ core know-how, Geneva OS, makes use of AI and automation to quickly generate clinical-grade proof from real-world information. Developed over almost a decade of analysis at Stanford, Geneva OS powers purposes like Atropos’ generative AI assistant ChatRWD. The platform allows clinicians, researchers, and different healthcare stakeholders to rapidly entry dependable scientific proof customized to particular affected person populations — one thing the corporate says is missing in healthcare right now.
“We discuss an idea referred to as the proof hole,” defined Hyde. “The stat that we now have is that solely about 14% of every day medical choices have any top quality proof behind them. That’s kind of stunning in case you’re not in our fields. However the causes for it are recognized — publications within the literature are pushed by scientific trials, we don’t run sufficient trials… What if we are able to use top quality information, analyzed appropriately and precisely, to fill that proof hole?”
Closing the proof hole: Personalised insights for higher affected person outcomes
Closing this “proof hole” is central to Atropos’ mission. The corporate believes offering clinicians with easy accessibility to customized proof primarily based on sufferers just like the one in entrance of them will result in higher outcomes. Hyde gave the instance of a doctor treating a coronary heart failure affected person:
“We’ve numerous affected person populations, they usually have comorbidities and totally different histories,” he stated. “What you really want is obvious proof for these subpopulations — proof that may not but exist in literature or scientific trials… Let’s not deal with each coronary heart failure affected person the identical. Let’s discover the proof for sure subgroups that generate higher outcomes and management prices for these sufferers.”
Accelerating pharmaceutical R&D with real-world proof automation
Functions of Atropos’ know-how prolong past point-of-care scientific choice making as effectively. The corporate has partnered with pharmaceutical giants like Janssen to speed up drug growth by producing proof to tell scientific trial design, affected person recruitment, and extra. Hyde instructed the platform might even be used to simulate scientific trials.
“What if we now have the flexibility to get nice proof and perception earlier to speed up your trial design and growth,” Hyde advised VentureBeat. “What if we are able to recruit extra successfully as a result of we now have that info, and extra trials are profitable? What if we might even simulate scientific trials and know beforehand which of them doubtless succeed or not? All that is about lowering cycle time in R&D and de-risking scientific trials.”
Atropos’ Sequence B comes at a time of accelerating curiosity in making use of generative AI to specialised domains like healthcare. However Hyde believes constructing belief by methodological rigor and transparency will likely be key to success.
“Whereas there’s been lots of pleasure round LLMs, frankly, most of it considerations us as a result of we’re frightened about hallucination charges,” he stated. “Geneva ensures that there’s no hallucinations, it’s scientific grade high quality, it’s extremely clear — a decade of publications on the way it’s accomplished — and customers can belief what’s popping out of it.”
With contemporary capital and a star-studded roster of strategic backers, Atropos is well-positioned to carry its imaginative and prescient of customized, automated scientific proof to healthcare globally. However Hyde emphasised that that is just the start:
“I believe proof is the forex of worth in healthcare… What if I might give [doctors] extra proof, and extra customized, so that they make a greater choice?” Hyde posited. “Basically, we’re attempting to maneuver the world to some extent the place all sufferers and all suppliers have entry to high quality, customized proof for his or her choice making.”